文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

Venetoclax增强减低强度预处理用于≥55岁高危髓系恶性肿瘤患者异基因外周血干细胞移植:一项II期研究

Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.
PubMed 文献 · Br J Haematol · 2026-07-15

中位随访14.9个月,1年无进展生存率72.5%,总生存率73.8%,GVHD/无复发生存率56.9%。TP53突变是 worse OS、PFS、GRFS及更高复发的独立预测因素,VEN-RIC可行且安全性可控。

要点

  • VEN-RIC在高危AML/MDS老年患者中1年PFS为72.5%,OS为73.8%。
  • 1年累积复发率16.8%,非复发死亡率10.6%,安全性可控。
  • TP53突变是OS、PFS、GRFS更差及复发更高的最强预测因素。

核心结论

  • VEN-RIC在高危AML或MDS的≥55岁患者中可行,并伴有鼓舞人心的生存率和可控的安全性,需随机研究证实。

主要发现

  • 中位随访14.9个月时,1年无进展生存率为72.5%,1年总生存率为73.8%,1年GVHD/无复发生存率为56.9%。
  • 1年累积复发率为16.8%,1年非复发死亡率为10.6%。
  • 180天急性GVHD累积发生率为22.9%,1年慢性GVHD累积发生率为25.8%。
  • 多因素分析显示TP53突变是更差OS、PFS、GRFS及更高复发的最强预测因素。

临床怎么用

  • 对于≥55岁高危AML或MDS行异基因外周血干细胞移植的患者,可考虑VEN-RIC方案,但需注意TP53突变提示预后不良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether venetoclax, an anti-leukaemic agent, can enhance RIC efficacy. A prospective, single-arm, phase 2 trial enrolled patients with high-risk AML or MDS, aged ≥55 years, who underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT). All patients received venetoclax-enhanced RIC (VEN-RIC), comprising venetoclax, busulfan, fludarabine, cytarabine and low-dose total body irradiation (TBI). Fifty patients (median age 62) were enrolled. At a median follow-up of 14.9 months, the 1-year progression-free survival (PFS) was 72.5%, while 1-year overall survival (OS) and graft-versus-host disease/relapse-free survival (GVHD/GRFS) were 73.8% and 56.9% respectively. The 1-year cumulative incidence of relapse and non-relapse mortality were 16.8% and 10.6%. The 180-day cumulative incidence of acute GVHD was 22.9%, while the 1-year cumulative incidence of chronic GVHD was 25.8%. Multivariable analysis showed TP53 mutation was the strongest predictor of worse OS, PFS and GRFS, as well as higher relapse. We conclude that VEN-RIC is feasible and associated with encouraging survival and a manageable safety profile, warranting confirmation in randomized studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gao J, Qiu H, Tong Y, et al. Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study. Br J Haematol. 2026. PMID: 42457583. doi:10.1111/bjh.70690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。